Chem Shift validation: AVS_full
BMRB Entry DOI: doi:10.13018/BMR52302
NMR-STAR file interactive viewer.
NMR-STAR v3 text file.
XML gzip file.
RDF gzip file.
All files associated with the entry
Citation: Paladini, Johannes; Maier, Annalena; Habazettl, Judith; Hertel, Ines; Sonti, Rajesh; Grzesiek, Stephan. "The molecular basis of Abelson kinase regulation by its aI-helix" eLife 12, 92324-92324 (2024).
PubMed: 38588001
Assembly members:
entity_1, polymer, 435 residues, 49605.31 Da.
entity_STI, non-polymer, 493.603 Da.
Natural source: Common Name: Human Taxonomy ID: 9606 Superkingdom: Eukaryota Kingdom: Metazoa Genus/species: Homo sapiens
Experimental source: Production method: recombinant technology Host organism: Escherichia coli Vector: pXI646
Data type | Count |
15N chemical shifts | 253 |
1H chemical shifts | 253 |
Entity Assembly ID | Entity Name | Entity ID |
---|---|---|
1 | SH3SH2KD | 1 |
2 | imatinib | 2 |
Entity 1, SH3SH2KD 435 residues - 49605.31 Da.
first two amino acids (GP) from cleavage site
1 | GLY | PRO | ASN | LEU | PHE | VAL | ALA | LEU | TYR | ASP | ||||
2 | PHE | VAL | ALA | SER | GLY | ASP | ASN | THR | LEU | SER | ||||
3 | ILE | THR | LYS | GLY | GLU | LYS | LEU | ARG | VAL | LEU | ||||
4 | GLY | TYR | ASN | HIS | ASN | GLY | GLU | TRP | CYS | GLU | ||||
5 | ALA | GLN | THR | LYS | ASN | GLY | GLN | GLY | TRP | VAL | ||||
6 | PRO | SER | ASN | TYR | ILE | THR | PRO | VAL | ASN | SER | ||||
7 | LEU | GLU | LYS | HIS | SER | TRP | TYR | HIS | GLY | PRO | ||||
8 | VAL | SER | ARG | ASN | ALA | ALA | GLU | TYR | LEU | LEU | ||||
9 | SER | SER | GLY | ILE | ASN | GLY | SER | PHE | LEU | VAL | ||||
10 | ARG | GLU | SER | GLU | SER | SER | PRO | GLY | GLN | ARG | ||||
11 | SER | ILE | SER | LEU | ARG | TYR | GLU | GLY | ARG | VAL | ||||
12 | TYR | HIS | TYR | ARG | ILE | ASN | THR | ALA | SER | ASP | ||||
13 | GLY | LYS | LEU | TYR | VAL | SER | SER | GLU | SER | ARG | ||||
14 | PHE | ASN | THR | LEU | ALA | GLU | LEU | VAL | HIS | HIS | ||||
15 | HIS | SER | THR | VAL | ALA | ASP | GLY | LEU | ILE | THR | ||||
16 | THR | LEU | HIS | TYR | PRO | ALA | PRO | LYS | ARG | ASN | ||||
17 | LYS | PRO | THR | VAL | TYR | GLY | VAL | SER | PRO | ASN | ||||
18 | TYR | ASP | LYS | TRP | GLU | MET | GLU | ARG | THR | ASP | ||||
19 | ILE | THR | MET | LYS | HIS | LYS | LEU | GLY | GLY | GLY | ||||
20 | GLN | TYR | GLY | GLU | VAL | TYR | GLU | GLY | VAL | TRP | ||||
21 | LYS | LYS | TYR | SER | LEU | THR | VAL | ALA | TYR | LYS | ||||
22 | THR | LEU | LYS | GLU | ASP | THR | MET | GLU | VAL | GLU | ||||
23 | GLU | PHE | LEU | LYS | GLU | ALA | ALA | VAL | MET | LYS | ||||
24 | GLU | ILE | LYS | HIS | PRO | ASN | LEU | VAL | GLN | LEU | ||||
25 | LEU | GLY | VAL | CYS | THR | ARG | GLU | PRO | PRO | PHE | ||||
26 | TYR | ILE | ILE | THR | GLU | PHE | MET | THR | TYR | GLY | ||||
27 | ASN | LEU | LEU | ASP | TYR | LEU | ARG | GLU | CYS | ASN | ||||
28 | ARG | GLN | GLU | VAL | ASN | ALA | VAL | VAL | LEU | LEU | ||||
29 | TYR | MET | ALA | THR | GLN | ILE | SER | SER | ALA | MET | ||||
30 | GLU | TYR | LEU | GLU | LYS | LYS | ASN | PHE | ILE | HIS | ||||
31 | ARG | ASP | LEU | ALA | ALA | ARG | ASN | CYS | LEU | VAL | ||||
32 | GLY | GLU | ASN | HIS | LEU | VAL | LYS | VAL | ALA | ASP | ||||
33 | PHE | GLY | LEU | SER | ARG | LEU | MET | THR | GLY | ASP | ||||
34 | THR | TYR | THR | ALA | HIS | ALA | GLY | ALA | LYS | PHE | ||||
35 | PRO | ILE | LYS | TRP | THR | ALA | PRO | GLU | SER | LEU | ||||
36 | ALA | TYR | ASN | LYS | PHE | SER | ILE | LYS | SER | ASP | ||||
37 | VAL | TRP | ALA | PHE | GLY | VAL | LEU | LEU | TRP | GLU | ||||
38 | ILE | ALA | THR | TYR | GLY | MET | SER | PRO | TYR | PRO | ||||
39 | GLY | ILE | ASP | LEU | SER | GLN | VAL | TYR | GLU | LEU | ||||
40 | LEU | GLU | LYS | ASP | TYR | ARG | MET | GLU | ARG | PRO | ||||
41 | GLU | GLY | CYS | PRO | GLU | LYS | VAL | TYR | GLU | LEU | ||||
42 | MET | ARG | ALA | CYS | TRP | GLN | TRP | ASN | PRO | SER | ||||
43 | ASP | ARG | PRO | SER | PHE | ALA | GLU | ILE | HIS | GLN | ||||
44 | ALA | PHE | GLU | THR | MET |
Entity 2, imatinib - C29 H31 N7 O - 493.603 Da.
1 | STI |
sample_1: Abl1 SH3-SH2-Kinase Domain (residues 83-515, isoform 1b), [U-99% 15N], 15 ± 0.8 uM; D2O, [U-2H], 5%; TRIS 10 mM; sodium chloride 100 mM; EDTA 2 mM; TCEP 2 mM; sodium azide 0.02 % w/v; H2O 95%; imatinib 45 ± 2.3 uM
sample_conditions_1: pH: 8; pressure: 1 atm; temperature: 303 K
Name | Sample | Sample state | Sample conditions |
---|---|---|---|
2D 1H-15N TROSY | sample_1 | isotropic | sample_conditions_1 |
TOPSPIN v3.6.2 - collection
NMRPipe - processing
NMRFAM-SPARKY - data analysis
Download HSQC peak lists in one of the following formats:
CSV: Backbone
or all simulated peaks
SPARKY: Backbone
or all simulated peaks